Drug Discovery Today 2014 v.19 №04

London, UK.: Elsevier. — 224 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Learning from ‘big data’: compounds and targets
Ye Hu and Jürgen BajorathDevelopment of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records
Kevin Wing, Ian Douglas, Krishnan Bhaskaran, Olaf H. Klungel, Robert F. Reynolds, Munir Pirmohamed, Liam Smeeth and Tjeerd P. van StaaMay disordered protein cause serious drug side effect?
Weng Ieong Tou and Calvin Yu-Chian ChenNF- signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities
Matthew J. Killeen, Mark Linder, Paolo Pontoniere and Roberto CreaToll-like receptors as therapeutic targets for cancer
Johanna HolldackThe end of KRAS, and other, cancers? A new way forward
Livio Mallucci and Valerie WellsmRNA display: from basic principles to macrocycle drug discovery
Kristopher Josephson, Alonso Ricardo and Jack W. SzostakIn situgelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations
Hugo Almeida, Maria Helena Amaral, Paulo Lobão and José Manuel Sousa LoboK_V7 potassium channels: a new therapeutic target in smooth muscle disorders
Jennifer B. Stott, Thomas A. Jepps and Iain A. GreenwoodPhosphoproteomics in drug discovery
Melody K. Morris, An Chi, Ioannis N. Melas and Leonidas G. AlexopoulosBig data in biomedicine
Fabricio F. CostaMoving forward in clinical trials for ALS: motor neurons lead the way please
Barıs¸ Genc ¸ and P. Hande ÖzdinlerGlutaminase regulation in cancer cells: a druggable chain of events
William P. Katt and Richard A. CerioneNeuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
Federica Barbieri, Manuela Albertelli, Federica Grillo, Amira Mohamed, Alexandru Saveanu,
Anne Barlier, Diego Ferone and Tullio FlorioDREADDs: novel tools for drug discovery and development
Hyeong-Min Lee, Patrick M. Giguere and Bryan L. RothMagnetic nanoparticles: a novel platform for cancer theranostics
Abhalaxmi Singh and Sanjeeb K. SahooTriterpenoids as reversal agents for anticancer drug resistance treatment
Xiao-Jian Yan, Li-Hua Gong, Fei-Yun Zheng, Ke-Jun Cheng, Zhe-Sheng Chen and Zhi ShiHow drug-like are ‘ugly’ drugs: do drug-likeness metrics predict ADME behaviour in humans?
Timothy J. Ritchie and Simon J.F. MacdonaldCollaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface
David M. Andrews, Martin E. Swarbrick and Andrew T. MerrittRecent progress in development of new sonosensitizers for sonodynamic cancer therapy
Haijun Chen, Xiaobin Zhou, Yu Gao, Biyuan Zheng, Fengxiang Tang and Jiandong HuangFragile X syndrome neurobiology translates into rational therapy
Sien Braat and R. Frank KooyAddendumDiary